IQZ23 

IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC₅₀=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders^[1].

IQZ23 activates AMPK pathway by modulating ATP synthase activity^[1].
IQZ23 (0.3 and 1.0 μM) markedly decreases the protein level of adipogenic factors C/EBPα, PPARγ, and sterol regulatory element-binding protein 1c (SREBP-1c)) after 24 h treatment as well as the level of fatty acid synthesis related proteins fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1) after 6 days of treatment in 3T3-L1 adipocytes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IQZ23 (20 mg/kg, i.p.) treatment significantly reverses high fat and cholesterol diet (HFC)- induced body weight increases and accompanying clinical symptoms of obesity in mice but without indicative toxicity^[1].
IQZ23 exhibits moderate terminal elimination half-lives (rat 4.2±0.3 h) and Cmax (rat 37.1±7.0 ng/mL) following oral administration (rat 5 mg/kg)^[1].
IQZ23 exhibits terminal elimination half-lives (rat 4.4±0.4 h) following intravenous administration (rat 2 mg/kg)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

443.54

C₂₆H₂₉N₅O₂

2415643-79-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yong Rao, et al. Discovery of a Promising Agent IQZ23 for the Treatment of Obesity and Related Metabolic Disorders. Eur J Med Chem. 2020 Apr 15;192:112172.  [Content Brief]